IPOGrid
Daily Spotlight · October 13, 2026
City Therapeutics Tests IPO Demand for an Early RNAi Pipeline
City Therapeutics asks IPO investors to fund an early RNAi pipeline
By Erik Aronesty · CITY THERAPEUTICS, INC. · CTY
CAMBRIDGE, Mass., October 13, 2026 • City Therapeutics is bringing one of the more institutionally credible early-stage biotech offerings of the fall to market. The RNA interference developer is seeking about $175 million at the midpoint, backed by ARCH...
Read by 900+ subscribers, 300+ of them at hedge funds.
IPOGrid Weekly · October 5, 2026 – October 11, 2026
Biotech IPOs cleared the calendar, then met a selective market
TRex held its offer price as Retension slipped
By Erik Aronesty · October 12, 2026
Weekly review: October 5 to October 11, 2026 Two clinical-stage biotechs completed U.S. IPOs on the same night, but the market delivered two very different verdicts. TRex Bio raised $116.7 million at the bottom of its range and finished its first session at...
Read by 900+ subscribers, 300+ of them at hedge funds.
IPO Calendar
Deals on the board
| Company | Deal | Status | Signal | Price | Gross Proceeds | Lead Underwriter | Exchange | Latest Form | Last Filing |
|---|---|---|---|---|---|---|---|---|---|
| ipo | effective | 10-15 to 10-27 | $16.00 | $150,000,000 | J.P. Morgan | Nasdaq Global Select Market | 8-A12B | 2026-10-13 | |
| ipo | effective | 10-15 to 10-27 | $18.00 | ~$174,999,996 | - | Nasdaq Global Market | 8-A12B | 2026-10-13 | |
|
Oura Inc.
OURA
|
ipo | amended | Watch | $40.00 to $44.00 | $2,100,000,000 | Goldman Sachs & Co. LLC | Nasdaq Global Select Market | FWP | 2026-09-24 |
| ipo | amended | Watch | $4.00 | $25,000,000 | ARC Group Securities LLC | Nasdaq Capital Market | F-1/A | 2026-09-29 | |
| ipo | amended | Watch | $11.00 | $42,900,000 | Kingswood Capital Partners, LLC | Nasdaq | F-1/A | 2026-09-24 | |
| ipo | amended | Watch | $4.50 | $18,000,000 | Alexander Capital, L.P. | NYSE American | S-1/A | 2026-09-30 | |
| ipo | amended | Active | $20.00 | $50,000,000 | WallachBeth Capital LLC | Nasdaq | S-1 | 2026-10-09 | |
|
AM PM Group Ltd
AMPM
|
ipo | amended | Active | $4.50 | $33,750,000 | Prime Number Capital LLC | Nasdaq Global Market | F-1/A | 2026-09-17 |
|
KiNRG, Inc.
BYOP
|
ipo | amended | Active | $6.00 | $18,000,000 | R.F. Lafferty & Co., Inc. | NYSE American | S-1/A | 2026-10-13 |
| ipo | amended | Active | $7.00 | $20,200,000 | ThinkEquity | NYSE American | S-1/A | 2026-10-13 | |
|
Amaero Inc.
AMRO
|
ipo | amended | Active | $5.15 | $19,983,496 | - | Nasdaq | S-1/A | 2026-10-08 |
|
Tracx Logis Ltd.
TRCX
|
ipo | amended | Active | $20.00 | $30,000,000 | Roth Capital Partners | Nasdaq Global Market | F-1/A | 2026-10-08 |
See full grid
Showing 12 exchange-focused names from 173 active public IPO issuers.
Active Signals
IPO filing and listing signals
Iambic Therapeutics, Inc.
IAM
$60M anchor demand
ARK Investment Management LLC and Duquesne Family Office LLC expressed indication of interest to purchase up to $60.0 million in shares at IPO price
Anchor interest from ARK Investment Management LLC and Duquesne Family Office LLC · $60M cornerstone indication · Cover banks: J.P. Morgan Securities LLC, Jefferies LLC, BofA Securities, Inc. +1 · Financial texture: Collaboration revenue $12,753
Forgent Power Solutions, Inc.
FPS
86% revenue growth
Revenues for the nine months ended March 31, 2026 were $958.4 million as compared to $515.6 million for the nine months ended March 31, 2025.
Cover banks: Goldman Sachs & Co. LLC, Jefferies LLC, Morgan Stanley & Co. LLC · Financial texture: Revenues for the nine months ended March 31, 2026 were $958.4 million as compared to $515.6 million for the nine months ended March 31, 2025.
Oura Inc.
OURA
Named anchor interest
Eli Lilly and Company indicated interest in $100.0M and Dragoneer Investment Group, LLC in $300.0M
Anchor interest from Eli Lilly and Company and Dragoneer Investment Group, LLC · Financial texture: Deterministic scale normalization applied to revenuePrior1, revenuePrior2, adjustedEbitdaCurrent, adjustedEbitdaPrior1, adjustedEbitdaPrior2,... · Deal terms: 14M shares · $0 price · $2.1B deal · Nasdaq OURA
Columbia Financial, Inc./MD/
CLBK
Operating company numbers
Total consolidated revenues $266,046 for 2025
Cover banks: Keefe, Bruyette & Woods, Inc. · Financial texture: Total consolidated revenues $266,046 for 2025 · Deal terms: 52M shares · $10 price · $1.9B deal · Timing: We anticipate simultaneously completing the conversion, the offering and the Northfield Bancorp acquisition...
CITY THERAPEUTICS, INC.
CTY
388% revenue growth
Collaboration revenue: Ocular (Bausch + Lomb) 2024 $ 2,778 2025 $ 7,123
Cover banks: Goldman Sachs & Co. LLC · Financial texture: Collaboration revenue: Ocular (Bausch + Lomb) 2024 $ 2,778 2025 $ 7,123 · Deal terms: 9.7M shares · $17-$19 · $185M deal · Nasdaq CTY
POP GLOBAL ACQUISITION Ltd
Named anchor interest
The Sponsor has committed to purchase private placement units, and Kingswood Capital Partners, LLC received representative shares as underwriting...
Anchor interest from Kingswood Capital Partners, LLC · $2.1M private placement from Sponsor · Cover banks: KINGSWOOD CAPITAL PARTNERS, LLC · Financial texture: Cash flows from operating activities: Net loss $ (15,000)